Coherus Biosciences | CHRS - Current Liabilities


Coherus Biosciences reported $140.39M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Akebia Therapeutics USD 173.88M 10.95M Mar/2026
ALKERMES USD 662.09M 62.59M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Amarin USD 164.2M 15.45M Jun/2026
Amgen USD 24.96B 534M Mar/2026
Baxter International USD 3.59B 102M Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Fujifilm JPY 1.26T 57.74B Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
Ironwood Pharmaceuticals USD 236.31M 5.91M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Myriad Genetics USD 130.7M 500K Jun/2026
Pacira USD 108.79M 11.8M Mar/2026
Perrigo USD 997.6M 15.3M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Teva Pharmaceutical Industries USD 15.65B 2.11B Jun/2026
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026
Xencor USD 73.46M 22.45M Mar/2026
Zoetis USD 2.05B 182M Mar/2026